The 503B deadline passes, closing large-scale semaglutide compounding

22 May 2025 ended the enforcement-discretion window for FDA-registered outsourcing facilities compounding semaglutide injection products that are essentially copies of the approved products.

This was the more consequential of the two deadlines commercially. 503B facilities supplied volume; 503A pharmacies supply individual prescriptions. Removing the 503B route removed the economics that had let telehealth platforms price compounded semaglutide at $150 to $400 a month at scale.

Reporting at the time put compounded versions at roughly 30% of total US GLP-1 supply at the 2024 peak, which is the scale of the market that had to restructure inside a few months.

What followed was consolidation: several large platforms exited compounded semaglutide, and the cheap end of the market moved to smaller operators.

How to read a regulatory story in this market

Three different things get conflated in coverage of this area: a proposal, an enforcement action and a final rule. Only the third changes what is lawful, and proposals have historically taken longer and landed narrower than early coverage suggested.

Check the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.

What this does not change

The prescription requirement, the licensing framework behind a dispensing pharmacy, and the clinical review that should sit in front of any prescription. Those are stable and none of the developments we track has altered them.

It also does not change the arithmetic of choosing a programme: price the dose you expect to hold, add every recurring fee, and verify the pharmacy. The cheapest verified route we track is NexLife at $145 a month all-in at a maintenance dose, about $1,740 for a first year.

Where a development does move those figures, the tables regenerate from the dataset on the next build rather than being edited by hand.

When urgency is the product

Regulatory and market news is routinely used as a sales device. A programme citing a rule change to push you into a twelve-month prepayment is using a real fact to manufacture a deadline that does not apply to you.

The test is simple: does the development change what you can lawfully be prescribed this month? Almost never. Does it change what you should pay? Sometimes. Does it require you to decide today? Essentially never — and a programme insisting otherwise has told you how it treats patients under commercial pressure.

Putting regulatory in proportion

It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.

The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.

What good looks like

A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.

The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.

What to ask before you pay

Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.

None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.

The failure mode this section guards against

Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew.

Each error is small alone and they compound in one direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated. Priced correctly the cheapest verified route sits at $145 a month all-in at a 2.4 mg maintenance dose.

Why we publish the working rather than a verdict

A single recommendation reads better and acts worse, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.

So the tables carry the inputs and every ranking states its sort key. Disagree with our weighting and you can take the file and weight it yourself — which is what publishing it is for.

The number most people get wrong

The month-six figure. Almost everyone budgets from the first month, which on semaglutide describes four weeks at 0.25 mg — roughly 1 mg of active drug against the 9.6 mg a maintenance month delivers.

Ten of your first twelve months are spent at or near maintenance. A ranking sorted on the advertised month is sorting on about eight per cent of your year, and on a dose-scaled programme those are different numbers entirely.

Run the first-year calculator at the dose you expect to hold. It takes under a minute and it reorders the market for most people.

What a year of this actually looks like

Four weeks at 0.25 mg, four at 0.5 mg, four at 1 mg, four at 1.7 mg, then 2.4 mg for the remainder. Sixteen weeks of titration if nothing is repeated, and repeats are common rather than exceptional.

Budget two extra months at a lower tier and treat anything better as upside. Fix a weekly injection day, record dose and date, and diary the renewal date if an introductory rate applies — the reversion is where most complaints in this category begin.

What this changes for what you pay

Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.

The cheapest verified compounded route we track currently sits at $145 a month all-in at a 2.4 mg maintenance dose, about $1,740 for a first year. Where a development moves that figure, our tables move with it on the next build.

How to verify this yourself

Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.

Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.